CHROMIUM PICOLINATE MONOHYDRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	3C6H4NO2.Cr.H2O
Molecular Weight	436.3158
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of CHROMIUM PICOLINATE MONOHYDRATE

Structure Search

SMILES

O.[Cr+3].[O-]C(=O)C1=NC=CC=C1.[O-]C(=O)C2=NC=CC=C2.[O-]C(=O)C3=NC=CC=C3

InChI

InChIKey=XIGVJNARZKLHPA-UHFFFAOYSA-K

InChI=1S/3C6H5NO2.Cr.H2O/c3*8-6(9)5-3-1-2-4-7-5;;/h3*1-4H,(H,8,9);;1H2/q;;;+3;/p-3

HIDE SMILES / InChI

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Cr
Molecular Weight	51.9961
Charge	3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C6H5NO2
Molecular Weight	123.1094
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10630581 | https://www.ncbi.nlm.nih.gov/pubmed/28954488

Chromium sulfate(III) hexahydrate or chromium sulphate, a trivalent compound of chromium that was investigated as a toxic compound. Experiments on rodent have shown chromium sulfate produced severe and widespread effects in the nasal cavity, larynx, lungs, and mediastinal lymph node. Effects were characterized by the accumulation of foreign material, infiltration of alveolar macrophages, septal cell hyperplasia, and granulomatous and chronic inflammation. Besides, chromium sulphate exerted a disadvantageous effect on the skeleton, as it decreases bone density and resistance.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
transmembrane receptor protein tyrosine kinase activity 22 Target ID: GO:0004714 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15924436	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chromium deficiency 22 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4d01ebb-a36e-44b7-028c-43c0ab2d13b4	Preventing		Approved 8429	CHROMIUM Approved Use Chromium 4 mcg/mL (Chromic Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition. Administration helps to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. Launch Date 2005

PubMed

Title	Date	PubMed
Status of antioxidant defense system in chromium-induced Swiss mice tissues.	2004 Jul	21782722

Patents

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:14:55 GMT 2023` Edited by `admin` on `Sat Dec 16 08:14:55 GMT 2023`
Record UNII	M6EBS2L3CB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CHROMIUM PICOLINATE MONOHYDRATE

Systematic Name

English

CHROMIUM, TRIS(2-PYRIDINECARBOXYLATO-.KAPPA.N1,.KAPPA.O2)-, MONOHYDRATE

Systematic Name

English

CHROMIUM, TRIS(2-PYRIDINECARBOXYLATO-.KAPPA.N1,.KAPPA.O2)-, HYDRATE (1:1)

Systematic Name

English

Code System Code Type Description

EPA CompTox

DTXSID8031025